Stoke Therapeutics (STOK) director awarded 17,786 options at $29.46 strike

Rhea-AI Filing Summary

Stoke Therapeutics director Adrian R. Krainer received a grant of 17,786 stock options to buy common shares at $29.46 each. These Director Stock Options were awarded for compensation, not purchased on the open market, and are held as a direct beneficial interest.

The options vest in full on the earlier of June 3, 2027 or the date of the company’s next annual stockholder meeting, as long as Krainer continues serving the company through that date. Following this grant, he holds 17,786 options covering the same number of common shares, which may be exercised before their expiration on June 2, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Krainer Adrian R.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	17,786	$0.00	--

Holdings After Transaction: Director Stock Option (Right to Buy) — 17,786 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Director stock options granted: 17,786 options Exercise price: $29.46 per share Underlying shares: 17,786 shares +3 more

6 metrics

Director stock options granted 17,786 options Grant of Director Stock Options reported on June 3, 2026

Exercise price $29.46 per share Exercise price for 17,786 Director Stock Options

Underlying shares 17,786 shares Common stock underlying the option grant

Total options after grant 17,786 options Total derivative securities held following the transaction

Vesting date trigger June 3, 2027 Earlier of this date or next annual stockholder meeting

Option expiration June 2, 2036 Expiration date of Director Stock Option grant

Key Terms

Director Stock Option (Right to Buy), exercise price, vesting, annual meeting of its stockholders

4 terms

Director Stock Option (Right to Buy) financial

"security_title: Director Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 29.4600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of its stockholders financial

"the date of the issuer's next annual meeting of its stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krainer Adrian R.

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$29.46	06/03/2026		A		17,786		(1)	06/02/2036	Common Stock	17,786	$0	17,786	D

Explanation of Responses:

1. The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.

	/s/ Jonathan Allan, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Adrian R. Krainer report in this Stoke Therapeutics (STOK) Form 4?

Adrian R. Krainer reported receiving a grant of 17,786 Director Stock Options for Stoke Therapeutics common stock. The options are compensation, not an open-market purchase, and give him the right to buy 17,786 shares at a fixed exercise price.

How many Stoke Therapeutics stock options were granted to Adrian R. Krainer?

He was granted 17,786 Director Stock Options covering 17,786 shares of Stoke Therapeutics common stock. This entire amount remains outstanding after the transaction, reflecting his full option position as reported in this filing.

What is the exercise price of Adrian R. Krainer’s Stoke Therapeutics options?

The exercise price of the granted Director Stock Options is $29.46 per share. This means Krainer can purchase Stoke Therapeutics common stock at $29.46 for each of the 17,786 underlying shares if he exercises the options.

When do Adrian R. Krainer’s Stoke Therapeutics director options vest?

The options vest in full on the earlier of June 3, 2027 or the date of Stoke Therapeutics’ next annual stockholder meeting. Vesting is conditional on his continued service to the company through the applicable vesting date.

When do the Stoke Therapeutics options granted to Adrian R. Krainer expire?

The Director Stock Options expire on June 2, 2036. After that date, any unexercised options will lapse, and Krainer will no longer have the right to buy the underlying Stoke Therapeutics common shares at the $29.46 exercise price.

Is Adrian R. Krainer’s Form 4 transaction a stock purchase or a compensation grant?

The filing shows a compensation grant of Director Stock Options, coded as an acquisition (A) for a grant or award. It is not an open-market stock purchase, but a right to buy shares at a fixed exercise price in the future.